An anti-Parkinson drug ropinirole depletes orexin from rat hypothalamic slice culture

Neuroscience Research

Volumn 68, Issue 4, 2010, Pages 315-321

  Michinaga, Shotaro ^a   Hisatsune, Akinori ^a   Isohama, Yoichiro ^a   Katsuki, Hiroshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

C Fos; Hypocretin; Melanin concentrating hormone; Pramipexole; Ropinirole; Sleep attack; Talipexole

Indexed keywords

DIZOCILPINE; DOPAMINE 2 RECEPTOR; MELANIN CONCENTRATING HORMONE; N METHYL DEXTRO ASPARTIC ACID; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; OREXIN; PICROTOXIN; PINDOLOL; PRAMIPEXOLE; ROPINIROLE; SEROTONIN 1A RECEPTOR; SULPIRIDE; TALIPEXOLE; YOHIMBINE;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CELL COUNT; CELL DEATH; CONTROLLED STUDY; HYPOTHALAMUS; IMMUNOREACTIVITY; NERVE CELL; NERVE CELL EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN DEPLETION; RAT; SLEEP; TISSUE CULTURE; WAKEFULNESS;

ANIMALS; ANTIPARKINSON AGENTS; FLUORESCENT ANTIBODY TECHNIQUE; HYPOTHALAMUS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICROSCOPY, CONFOCAL; NEURONS; NEUROPEPTIDES; ORGAN CULTURE TECHNIQUES; RATS; RATS, WISTAR;

EID: 78149468269     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2010.08.005     Document Type: Article

References (32)

1. Alberto C.O., Trask R.B., Quinlan M.E., Hirasawa M. Bidirectional dopaminergic modulation of excitatory synaptic transmission in orexin neurons. J. Neurosci. 2006, 26:10043-10050.
2. Bubser M., Fadel J.R., Jackson L.L., Meador-Woodruff J.H., Jing D., Deutch A.Y. Dopaminergic regulation of orexin neurons. Eur. J. Neurosci. 2005, 21:2993-3001.
3. Chemelli R.M., Willie J.T., Sinton C.M., Elmquist J.K., Scammell T., Lee C., Richardson J.A., Williams S.C., Xiong Y., Kisanuki Y., Fitch T.E., Nakazato M., Hammer R.E., Saper C.B., Yanagisawa M. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
4. Eggermann E., Bayer L., Serafin M., Saint-Mleux B., Bernheim L., Machard D., Jones B.E., Muhlethaler M. The wake-promoting hypocretin-orexin neurons are in an intrinsic state of membrane depolarization. J. Neurosci. 2003, 23:1557-1562.
5. Foley P., Gerlach M., Double K.L., Riederer P. Dopamine receptor agonists in the therapy of Parkinson's disease. J. Neural. Transm. 2004, 111:1375-1446.
6. Fronczek R., Overeem S., Lee S.Y., Hegeman I.M., van Pelt J., van Duinen S.G., Lammers G.J., Swaab D.F. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007, 130:1577-1585.
7. Frucht S., Rogers J.D., Greene P.E., Gordon M.F., Fahn S. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999, 52:1908-1910.
8. Gerlach M., Double K., Arzberger T., Leblhuber F., Tatschner T., Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J. Neural. Transm. 2003, 110:1119-1127.
9. Greer P.L., Greenberg M.E. From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron 2008, 59:846-860.
10. Hobson D.E., Pourcher E., Martin W.R. Ropinirole and pramipexole, the new agonists. Can. J. Neurol. Sci. 1999, 26:S27-33.
11. Horvath J., Fross R.D., Kleiner-Fisman G., Lerch R., Stalder H., Liaudat S., Raskoff W.J., Flachsbart K.D., Rakowski H., Pache J.C., Burkhard P.R., Lang A.E. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord. 2004, 19:611-613.
12. Horvath T.L., Gao X.B. Input organization and plasticity of hypocretin neurons: possible clues to obesity's association with insomnia. Cell Metab. 2005, 1:279-286.
13. Kato H., Hosoda H., Fukuda T., Masushige S., Kida S. Characterization of the promoter of the mouse preproorexin gene. Biosci. Biotechnol. Biochem. 2007, 71:840-843.
14. Katsuki H., Akaike A. Excitotoxic degeneration of hypothalamic orexin neurons in slice culture. Neurobiol. Dis. 2004, 15:61-69.
15. Katzenschlager R., Lees A.J. Treatment of Parkinson's disease: levodopa as the first choice. J. Neurol. 2002, 249(Suppl. 2):II19-II24.
16. Li Y., Gao X.B., Sakurai T., van den Pol A.N. Hypocretin/orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron 2002, 36:1169-1181.
17. Li Y., van den Pol A.N. Direct and indirect inhibition by catecholamines of hypocretin/orexin neurons. J. Neurosci. 2005, 25:173-183.
18. Lee M.G., Hassani O.K., Jones B.E. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J. Neurosci. 2005, 25:6716-6720.
19. Lossi L., Alasia S., Salio C., Merighi A. Cell death and proliferation in acute slices and organotypic cultures of mammalian CNS. Prog. Neurobiol. 2009, 88:221-245.
20. Michinaga S., Hisatsune A., Isohama Y., Katsuki H. Inhibition of neural activity depletes orexin from rat hypothalamic slice culture. J. Neurosci. Res. 2010, 88:214-221.
21. Mileykovskiy B.Y., Kiyashchenko L.I., Siegel J.M. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 2005, 46:787-798.
22. 1A receptor. J. Neurosci. 2004, 24:7159-7166.
23. 2, receptor subtypes. J. Pharmacol. Exp. Ther. 2002, 303:815-822.
24. Nishino S., Ripley B., Overeem S., Nevsimalova S., Lammers G.J., Vankova J., Okun M., Rogers W., Brooks S., Mignot E. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol. 2001, 50:381-388.
25. Paus S., Brecht H.M., Köster J., Seeger G., Klockgether T., Wüllner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov. Disord. 2003, 18:659-667.
26. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., Nevsimalova S., Aldrich M., Reynolds D., Albin R., Li R., Hungs M., Pedrazzoli M., Padigaru M., Kucherlapati M., Fan J., Maki R., Lammers G.J., Bouras C., Kucherlapati R., Nishino S., Mignot E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 2000, 6:991-997.
27. Ravikumar K., Sridhar B. Ropinirole hydrochloride, a dopamine agonist. Acta Crystallogr. C 2006, 62:o265-267.
28. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat. Rev. Neurosci. 2007, 8:171-181.
29. Scammell T.E. The neurobiology, diagnosis, and treatment of narcolepsy. Ann. Neurol. 2003, 53:154-166.
30. Steiger M., Jost W., Grandas F., Van Camp G. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J. Neural Transm. 2009, 116:179-191.
31. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., Cornford M., Siegel J.M. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
32. Thannickal T.C., Lai Y.Y., Siegel J.M. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595.